Analysis of Individual Patient Data Demonstrates that Sublobar Resection Followed by Adjuvant Chemotherapy has Equivalent Prognosis to Lobectomy in Patients with Stage I NSCLC with Spread through Air Spaces
- PMID: 40781382
- DOI: 10.1245/s10434-025-17871-z
Analysis of Individual Patient Data Demonstrates that Sublobar Resection Followed by Adjuvant Chemotherapy has Equivalent Prognosis to Lobectomy in Patients with Stage I NSCLC with Spread through Air Spaces
Abstract
Background: Lobectomy (LOB) remains the standard treatment for stage I non-small cell lung cancer (NSCLC), though sublobar resection (SLR) has emerged as a potential alternative with comparable outcomes. Spread through air spaces (STAS) has been confirmed as an independent risk factor after lung cancer surgery. The prognosis differences between LOB and SLR in patients with stage I NSCLC with STAS are controversial.
Patients and methods: After systematic retrieval across multiple databases, 25 eligible studies involving 14,126 patients were identified. We extracted hazard ratios (HRs) for recurrence-free survival (RFS) and overall survival (OS) comparing lobectomy versus sublobar resection, along with reconstructed individual patient data (IPD) and adjuvant chemotherapy (ACT) records. These datasets were subsequently subjected to meta-analysis with complementary subgroup and sensitivity analyses.
Results: STAS was confirmed as an independent risk factor (RFS: HR 2.61, 95% CI 2.17-3.14; OS: HR 2.15, 95% CI 1.75-2.63). In subgroup analysis of SLR versus LOB in patients with STAS, the inferior RFS and comparable OS were observed in the SLR group (RFS: HR 1.70, 95% CI 1.16-2.49, n = 3488; OS: HR 1.10, 95% CI 0.83-1.46, n = 3581). Furthermore, ACT following SLR effectively reduced recurrence risk in STAS-positive patients compared with LOB (LOB: RFS: HR 1.03, 95% CI 0.48-2.22; SLR: RFS: HR 0.44, 95% CI 0.23-0.82).
Conclusions: Surgical approach significantly impacts survival outcomes in stage I NSCLC patients with STAS. LOB remains the preferred option due to its lower recurrence rate and prolonged survival outcomes; for high-risk patients undergoing SLR, ACT is recommended in the case of postoperative STAS.
Keywords: Adjuvant chemotherapy; Lobectomy; Prognosis; Spread through air spaces; Sublobar resection.
© 2025. Society of Surgical Oncology.
Conflict of interest statement
Disclosure: The authors declare they have no conflict of interest. Ethical approval: No ethical approval was required since the data were extracted from already published studies.
Similar articles
-
Could less be enough: sublobar resection vs lobectomy for clinical stage IA non-small cell lung cancer patients with visceral pleural invasion or spread through air spaces.Int J Surg. 2025 Mar 1;111(3):2675-2685. doi: 10.1097/JS9.0000000000002249. Int J Surg. 2025. PMID: 39878072 Free PMC article.
-
Benefit of adjuvant chemotherapy for resected stage I lung cancer with spread through air spaces: a systematic review and meta-analysis.Eur J Surg Oncol. 2025 Aug;51(8):110104. doi: 10.1016/j.ejso.2025.110104. Epub 2025 Apr 25. Eur J Surg Oncol. 2025. PMID: 40347714
-
Prognostic significance of tumor spread through air spaces and lymphovascular invasion in stage I non-small cell lung cancer: implications for adjuvant chemotherapy.World J Surg Oncol. 2025 Aug 28;23(1):325. doi: 10.1186/s12957-025-03980-2. World J Surg Oncol. 2025. PMID: 40877958 Free PMC article.
-
Sublobar resection is non-inferior to lobectomy in octogenarians and older with stage Ia non‑small cell lung cancer.Transl Cancer Res. 2025 May 30;14(5):2966-2980. doi: 10.21037/tcr-2024-2575. Epub 2025 May 14. Transl Cancer Res. 2025. PMID: 40530121 Free PMC article.
-
Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation.Cochrane Database Syst Rev. 2025 May 27;5(5):CD015140. doi: 10.1002/14651858.CD015140.pub2. Cochrane Database Syst Rev. 2025. PMID: 40421698 Review.
References
-
- Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660 . - DOI - PubMed
-
- Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer lung cancer study group. Ann Thorac Surg. 1995;60(3):615–22. https://doi.org/10.1016/0003-4975(95)00537-u . - DOI - PubMed
-
- Saji H, Okada M, Tsuboi M, et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet Lond Engl. 2022;399(10335):1607–17. https://doi.org/10.1016/S0140-6736(21)02333-3 . - DOI
-
- Wolf AS, Richards WG, Jaklitsch MT, et al. Lobectomy versus sublobar resection for small (2 cm or less) non-small cell lung cancers. Ann Thorac Surg. 2011;92(5):1819–23. https://doi.org/10.1016/j.athoracsur.2011.06.099 . - DOI - PubMed
-
- Winckelmans T, Decaluwé H, De Leyn P, Van Raemdonck D. Segmentectomy or lobectomy for early-stage non-small-cell lung cancer: a systematic review and meta-analysis. Eur J Cardiothorac Surg. 2020;57(6):1051–60. https://doi.org/10.1093/ejcts/ezz339 . - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources